COMMUNIQUÉS West-GlobeNewswire

Addex Therapeutics Announces Executive Management Changes
02/10/2026
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex [...]
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
02/10/2026
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational [...]
Ending MS Is Within Reach: National MS Society Raises a Record-Breaking $12 Million to Launch the Campaign to End MS
02/10/2026
Nearly 500 guests gathered at Cipriani 42nd Street for the Campaign to End MS Gala, emceed by Ginger Zee and honoring David Osmond and his family, as the Society kicked off its five-year, $1 billion campaign NEW YORK, [...]
Wandercraft Acquires Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility
02/10/2026
End-to-end continuum of care, powered by medical exoskeletons, an expanded global clinical network, and trailblazing R&D capabilities, expands options for upright mobility, from rehabilitation to everyday life NEW [...]
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
02/10/2026
TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting [...]
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
02/10/2026
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time [...]
Nutraville Introduces Pineal Guardian Advanced, a Liquid Botanical Formula Designed to Support Pineal Gland and Cognitive Wellness
01/10/2026
Tallmadge, OH, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nutraville is expanding its healthy-aging portfolio with Pineal Guardian Advanced, a liquid botanical formula that combines 11 nutritional and plant-based ingredients to [...]
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
01/10/2026
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock DALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE [...]
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
01/10/2026
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group [...]
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
01/10/2026
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel [...]
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
01/10/2026
MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly- [...]
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
01/10/2026
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
01/10/2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
01/10/2026
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums CERRITOS, Calif., Oct. 01, 2026 (GLOBE [...]
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
01/10/2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in [...]
NANOBIOTIX annonce la nomination d’Arnd Christ au poste de directeur financier
01/10/2026
PARIS et CAMBRIDGE, Mass., 01 oct. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

Pages